Secondary Logo

Journal Logo

Central nervous system drugs

Bridgeman, Mary Barna PharmD, BCPS, BCGP; Dalal, Kavitha S. PharmD

doi: 10.1097/01.NURSE.0000553283.33966.7d

Can you identify these central nervous system drugs?

Mary Barna Bridgeman is a clinical associate professor at Rutgers University Ernest Mario School of Pharmacy in Piscataway, N.J. Kavitha S. Dalal is a critical care pharmacist at Virtua in Marlton, N.J.

Unless otherwise specified, the information in the preceding summaries applies to adults, not children. Consult the package insert for information about each drug's safety during pregnancy and breastfeeding. Also consult a pharmacist, the package insert, or a comprehensive drug reference for more details on precautions, drug interactions, and adverse reactions.

CAN YOU IDENTIFY these drugs indicated for central nervous system disorders? To find out, match each brand name in Section I with its generic name in Section II.

Back to Top | Article Outline

Section I

_____ 1. Briviact (UCB, Inc.)

_____ 2. Aimovig (Amgen)

_____ 3. Austedo (Teva Pharmaceuticals USA, Inc.)

Back to Top | Article Outline

Section II

a. brivaracetam. This medication is indicated to treat partial-onset seizures in patients age 4 years or older as either monotherapy or in conjunction with other medications. It is available in three forms—oral tablets, oral solution, and I.V. injection—but the I.V. formulation is indicated only for patients age 16 and older because its safety in younger patients has not been established. Monitor patients for suicidal behaviors or thoughts; other neurologic or psychiatric adverse reactions such as sedation; and hypersensitivity reactions.

b. erenumab-aooe. Administered as a once-monthly subcutaneous injection, this drug is prescribed for preventive treatment of episodic or chronic migraine in adults. This monoclonal antibody, which works as an antagonist to the calcitonin gene-related peptide receptor, represents a new class of medications indicated for migraine relief. Teach patients to self-administer subcutaneous injections in the abdomen, thigh, or upper arm via use of a prefilled autoinjector syringe.

c. deutetrabenazine. Granted Orphan Drug Designation by the FDA, deutetrabenazine is the second medication approved for treatment of the spastic, jerking movements (chorea) associated with Huntington disease and is also approved to treat tardive dyskinesia in adults. This medication is administered as a once-daily oral tablet and carries a Boxed Warning about the risk of suicidality and depression in patients with Huntington disease.

Resources available upon request

ANSWERS: 1a, 2b, 3c

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.